Shots: 

• The US FDA has approved Ohtuvayre as a maintenance therapy to treat COPD patients, with its launch anticipated in Q3’24 

• The approval was based on the P-III (ENHANCE-1 & ENHANCE-2) studies analyzing Ohtuvayre monotx. or in addition with other maintenance therapies. Trials reached their 1EPs showing improved lung function; results were published in the American Journal of Respiratory and Critical Care Medicine 

• Ohtuvayre is a dual PDE3 & PDE4 inhibitor which possesses both bronchodilator & non-steroidal anti-inflammatory activities. It is administered using a standard jet nebulizer into the lungs  

Ref: Verona Pharma | Image: Verona Pharma

Related Post:- Verona Pharma Reports the US FDA Acceptance of NDA for Ensifentrine to Treat Chronic Obstructive Pulmonary Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com